Single-Use Bioprocessing Market Report

Furthermore, the US with USD 6.4 billion market in 2024, held a largest share in the single-use bioprocessing market.

• Thermo Fisher Scientific Inc. (US) launched its DynaDrive 5L Single-Use Bioreactor, expanding its portfolio of bioreactors. This addition provides researchers and manufacturers with a scalable and user-friendly solution for cell culture and bioprocessing at smaller scales, supporting early-stage research, process development, and pilot production in the biopharmaceutical industry. (April 14, 2025)
• Sartorius Ag (Germany) partnered with Tulip Interfaces, Inc. (US), a provider of digital manufacturing solutions, to integrate Tulip’s factory intelligence platform with Sartorius’s bioprocessing technologies. This collaboration aims to provide end-to-end visibility and optimization across biomanufacturing operations, enhancing efficiency and productivity in the biopharmaceutical industry. (April 9, 2025)
• Novo Nordisk A/S (Denmark) acquired Sealing Systems A/S (Denmark), this acquisition aims to enhance supply chain resilience, control quality closer to final production, and potentially reduce costs, strengthening Novo Nordisk’s position as a major biotech player by managing more of its own upstream manufacturing inputs. (May 16, 2024)

Drivers: Increased production of therapeutic proteins and antibodies drives the single-use bioprocessing market growth.

The increasing production of therapeutic proteins and antibody-based drugs is a major driver for the single-use bioprocessing market. This surge is largely fueled by two key factors like enhanced scalability and reduced contamination risk. Single-use systems offer unparalleled scalability, allowing manufacturers to easily adjust production volumes to meet growing demand or accommodate different clinical trial sizes without the high costs and complexity associated with cleaning traditional stainless-steel equipment between batches. This flexibility is crucial for the development and commercialization of complex biologics. Furthermore, the inherent nature of single-use systems virtually eliminates cross-contamination between batches, a critical advantage when producing sensitive therapeutic proteins and antibodies that must meet stringent purity and safety standards. These benefits make single-use technology an increasingly preferred solution, accelerating biologic manufacturing and directly boosting the demand for related products and services.

Opportunities: Rising demand for personalized medicines drives single-use bioprocessing demand

The rising demand for personalized medicines is significantly driving the single-use bioprocessing market, as these therapies require smaller, customized production batches that are difficult to achieve efficiently with traditional stainless-steel systems. This surge is accelerated by advancements in genomics and targeted therapies, leading to a greater variety of complex treatments tailored to individual patient needs. As developers seek manufacturing solutions that offer flexibility, speed, and scalability to match this bespoke approach, single-use systems are increasingly favored for their ability to quickly adapt to varying batch sizes and reduce contamination risks between unique batches. Consequently, manufacturers are investing heavily in single-use technologies, making them a key enabler for the future of precision medicine and fueling substantial growth in the bioprocessing sector.

Challenges: Extractables/leachable compliance limit single-use bioprocessing growth

The bioprocessing industry faces significant challenges related to extractables and leachable (E&L) compliance, stemming from the need to ensure the safety and purity of therapeutic products. Identifying and quantifying potential chemical compounds migrating from single-use system components into the drug product requires extensive testing and complex risk assessments. Meeting stringent regulatory expectations regarding E&L profiles adds considerable complexity, cost, and time to the development and manufacturing process. Navigating these challenges is crucial for ensuring patient safety and maintaining regulatory approval, making E&L management a critical factor in bioprocess design and execution.

The global single-use bioprocessing market is experiencing strong expansion, driven by the increasing production of therapeutic proteins, antibodies, and advanced therapies like cell and gene treatments. Valued at USD 16.2 billion in 2024, this market is projected to grow at a CAGR of 13.5%, potentially reaching USD 34.6 billion by 2030. Key factors fueling this growth include the advantages of single-use systems such as cost efficiency, scalability, faster turnaround times, reduced contamination risks, and increasing outsourcing to CDMOs. The market landscape is characterized by technological advancements in automation and sensors, supportive regulatory frameworks, and a shift towards flexible and decentralized manufacturing models. North America currently holds the largest market share, while the Asia-Pacific region is expected to exhibit the highest growth rate due to significant investments and a thriving CDMO sector.